All News

Gout pills injection

Allopurinol Use Does Not Increase Mortality in Gout with Chronic Kidney Disease

d Jack Cush, MD

A population based trial has shown that allopurinol use dose escalation and achieving target uric acid levels (with allopurinol), was not associated with increased mortality in patients with gout and concurrent CKD

Read Article
RA, hands, MCP, deformity

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

d MedPage Today

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.

Read Article
FDA%20approved.jpg (keep)

Upadacitinib FDA Approved for Ankylosing Spondylitis

d Jack Cush, MD

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

Read Article
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
Retrospective study of 71 adult-onset Still’s disease pts Rx 1st w/ High-dose glucocorticoids shows 41% failed to respond (poor outcome) by week4 w/ WBC as best predictor. If WBC < 13K 60% responded; if ≥13K only 23.5% https://t.co/tMNDgoqP14 https://t.co/xJrIEUU6iK

Links:

Dr. John Cush RheumNow ( View Tweet)
TLR7 signaling impt to SLE as it drives type I IFN & activation of autoreactive B cells. Nature reports missense TLR7 (Y264H) variant from severe lupus induces guanosine & cGMP & causes murine lupus when introduced into mice. https://t.co/mzAWd3Pke8 https://t.co/knwa7fBLxk

Links:

Dr. John Cush RheumNow ( View Tweet)
"Belt & Suspenders" strategy - both COVID-19 vaccination & PrEP (Evusheld) needed to prevent SARS-CoV-2 in moderately to severely immunocompromised pts (transplant, cancer, immunodeficiency) and active poorly controlled autoimmune Dz https://t.co/RmflniD7rD https://t.co/K7pmQtqcOb

Links:

Dr. John Cush RheumNow ( View Tweet)
TONIGHT! Join us at for Tuesday Night Rheumatology at 7pm ET. This webinar will share highlights from these lectures followed by live audience Q & A: Treatment Choices in Refractory RA Adherence to Rheumatoid Therapies Precision Medicine in RA https://t.co/8t6z8Y3JR9 https://t.co/xmIRA7faP5

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatologic diagnosis through hand exam by Dr. Sarah Chung @ACPinternists #rheumatology #rheumtwitter #MedEd #rheumatoidarthritis #BJHM #Hospitalmedicine #IM2022 #MedTwitter 👇🏽 https://t.co/qR4zNa4NcX
Brown Journal of Hospital Medicine BrownJHM ( View Tweet)
Patient with new onset Colitis while on secukinumab, but is this drug-induced? https://t.co/tpipGFOHI4 https://t.co/h4QujJdU8O

Links:

Dr. John Cush RheumNow ( View Tweet)
Leflunomide responses in #RA assoc w/ high metabolite levels (A77 1726). In 115 LEF Rx Pts, 40% had LDAS/remission. A77 1726 levels neg correlation w/ DAS28-ESR (r = − 0.42, p < 0.001). Levels >10µg/mL & LDAS PPV 70%; NPV 93% https://t.co/V32wUGVWLM https://t.co/L9DwZBwet9

Links:

Dr. John Cush RheumNow ( View Tweet)
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/NiPTbknD57 https://t.co/HOC2Bev4R6

Links:

Dr. John Cush RheumNow ( View Tweet)
We completed a whole month of super-charged, focused coverage & education on #PsA.THANKS to the many mavens who contributed! In PSA - "Unless someone like you cares a whole awful lot, nothing is going to get better. It’s not." -Dr. Seuss, The Lorax https://t.co/Y58klwbS4V https://t.co/f2pnuypwyr

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 33 #RA pts finds nearly half had peripheral neuropathy (48.5%); sensorimotor in 64.7%, motor in 17.6%. Neuropathy was NOT associated with age, gender, disease activity, functionality, or falls https://t.co/r2aQI2cm27 https://t.co/OOQlWkCAft

Links:

Dr. John Cush RheumNow ( View Tweet)
Prolonged TNF Inhibitor Use Delays Sacroiliac Progression https://t.co/dz4d8q8XSy https://t.co/NWCAb0OH7B

Links:

Dr. John Cush RheumNow ( View Tweet)
Intraarticular Steroids in Hip Osteoarthritis - Do They Work? https://t.co/AP9jo96xQo https://t.co/tYvP20Qpqh

Links:

Dr. John Cush RheumNow ( View Tweet)
Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion about two important studies. https://t.co/RjFRFt6oJQ https://t.co/zOxCDC1atS

Links:

Dr. John Cush RheumNow ( View Tweet)
Biologics for JIA? Not So Fast, Say Insurers It's not a simple matter to prescribe tumor necrosis factor (TNF) inhibitors for patients with juvenile idiopathic arthritis (JIA), at least those with insurance, a single-center study found. https://t.co/w4A5sgv3fU https://t.co/coVh3zui2z

Links:

Dr. John Cush RheumNow ( View Tweet)
Arthritis Predicts Hepatic Fibrosis in Hemochromatosis https://t.co/AHnRkvq2wo https://t.co/zbl3HQRZCX

Links:

Dr. John Cush RheumNow ( View Tweet)
Today the FDA expanded the indications for upadacitinib (Rinvoq) to include ankylosing spondylitis - specifically for adults w/ active ankylosing spondylitis after failing a TNF blockers or other DMARDs. https://t.co/A9QhT98Djj

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×